CLU and breast cancer: To explore the potential of the clusterin inhibition approach in breast cancer therapy, the cytotoxic interaction between antisense clusterin oligonucleotide or anticlusterin antibody and the drugs commonly used in breast cancer treatment such as dexamethasone, doxorubicin, paclitaxel, and tamoxifen were analyzed in vitro using the breast carcinoma cell lines MCF-7 and MDA-MB-231.